87 related articles for article (PubMed ID: 15829299)
21. Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Zhao Q; Ma L; Jiang S; Lu H; Liu S; He Y; Strick N; Neamati N; Debnath AK
Virology; 2005 Sep; 339(2):213-25. PubMed ID: 15996703
[TBL] [Abstract][Full Text] [Related]
22. Molecular insights into the inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody.
Hou W; Fang C; Liu J; Yu H; Qi J; Zhang Z; Yuan R; Xiong D; Gao S; Adam Yuan Y; Li S; Gu Y; Xia N
Antiviral Res; 2015 Oct; 122():101-11. PubMed ID: 26259811
[TBL] [Abstract][Full Text] [Related]
23. Biological activities on T lymphocytes of a baculovirus-expressed chimeric recombinant IgG1 antibody with specificity for the CDR3-like loop on the D1 domain of the CD4 molecule.
Troadec S; Bès C; Chentouf M; Nguyen B; Briant L; Jacquet C; Chebli K; Pugnière M; Roquet F; Cerutti M; Chardès T
Clin Immunol; 2006 Apr; 119(1):38-50. PubMed ID: 16426893
[TBL] [Abstract][Full Text] [Related]
24. HIV inhibition by CD4 and CCR5-derived glycopeptides.
Perdomo MF; Sällberg M; Vahlne A
AIDS Res Hum Retroviruses; 2012 Sep; 28(9):1052-8. PubMed ID: 22559037
[TBL] [Abstract][Full Text] [Related]
25. Enhancement of soluble CD4-mediated HIV neutralization and gp 120 binding by CD4 autoantibodies and monoclonal antibodies.
Moore JP; Sattentau QJ; Clapham PR
AIDS Res Hum Retroviruses; 1990 Nov; 6(11):1273-9. PubMed ID: 2078408
[TBL] [Abstract][Full Text] [Related]
26. Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates.
Chen W; Xiao X; Wang Y; Zhu Z; Dimitrov DS
Antiviral Res; 2010 Oct; 88(1):107-15. PubMed ID: 20709110
[TBL] [Abstract][Full Text] [Related]
27. Combining human antisera to human leukocyte antigens, HIVgp120 and 70 kDa heat shock protein results in broadly neutralizing activity to HIV-1.
Babaahmady K; Bergmeier LA; Lehner T
AIDS; 2008 Jul; 22(11):1267-76. PubMed ID: 18580605
[TBL] [Abstract][Full Text] [Related]
28. HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats.
Bosch V; Pfeiffer T; Devitt G; Allespach I; Ebensen T; Emerson V; Guzman CA; Keppler OT
Vaccine; 2009 Apr; 27(16):2202-12. PubMed ID: 19428834
[TBL] [Abstract][Full Text] [Related]
29. Modification of the Fc region of a primatized IgG antibody to human CD4 retains its ability to modulate CD4 receptors but does not deplete CD4(+) T cells in chimpanzees.
Newman R; Hariharan K; Reff M; Anderson DR; Braslawsky G; Santoro D; Hanna N; Bugelski PJ; Brigham-Burke M; Crysler C; Gagnon RC; Dal Monte P; Doyle ML; Hensley PC; Reddy MP; Sweet RW; Truneh A
Clin Immunol; 2001 Feb; 98(2):164-74. PubMed ID: 11161972
[TBL] [Abstract][Full Text] [Related]
30. Generation and characterization of a single-gene mouse-human chimeric antibody against hepatitis B surface antigen.
Bose B; Khanna N; Acharya SK; Sinha S
J Gastroenterol Hepatol; 2006 Sep; 21(9):1439-47. PubMed ID: 16911690
[TBL] [Abstract][Full Text] [Related]
31. [Analysis of the principal neutralization site of HIV-1 and vaccine research].
Okamoto Y; Honda M
Tanpakushitsu Kakusan Koso; 1997 May; 42(7 Suppl):1201-8. PubMed ID: 9170954
[No Abstract] [Full Text] [Related]
32. Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.
Huskens D; Van Laethem K; Vermeire K; Balzarini J; Schols D
Virology; 2007 Apr; 360(2):294-304. PubMed ID: 17123566
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
Bosch B; Blanco J; Pauls E; Clotet-Codina I; Armand-Ugón M; Grigorov B; Muriaux D; Clotet B; Darlix JL; Esté JA
Antimicrob Agents Chemother; 2005 Oct; 49(10):4296-304. PubMed ID: 16189111
[TBL] [Abstract][Full Text] [Related]
34. A recombinant allosteric lectin antagonist of HIV-1 envelope gp120 interactions.
McFadden K; Cocklin S; Gopi H; Baxter S; Ajith S; Mahmood N; Shattock R; Chaiken I
Proteins; 2007 May; 67(3):617-29. PubMed ID: 17348010
[TBL] [Abstract][Full Text] [Related]
35. Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors.
Yoshimura K; Shibata J; Kimura T; Honda A; Maeda Y; Koito A; Murakami T; Mitsuya H; Matsushita S
AIDS; 2006 Oct; 20(16):2065-73. PubMed ID: 17053352
[TBL] [Abstract][Full Text] [Related]
36. Enhancement of human immunodeficiency virus type 1 envelope-mediated fusion by a CD4-gp120 complex-specific monoclonal antibody.
Lee S; Peden K; Dimitrov DS; Broder CC; Manischewitz J; Denisova G; Gershoni JM; Golding H
J Virol; 1997 Aug; 71(8):6037-43. PubMed ID: 9223495
[TBL] [Abstract][Full Text] [Related]
37. CD4 immunoadhesins in anti-HIV therapy: new developments.
Chamow SM; Duliege AM; Ammann A; Kahn JO; Allen JD; Eichberg JW; Byrn RA; Capon DJ; Ward RH; Ashkenazi A
Int J Cancer Suppl; 1992; 7():69-72. PubMed ID: 1428410
[TBL] [Abstract][Full Text] [Related]
38. Cloning and biological characterization of human single-chain Fv fragments that mediate neutralization of HIV-1.
Srikantan V; Wang B; Satre MA; Ugen KE; Dang K; Scales F; Godillot AP; Williams WV; Weiner DB
AIDS; 1994 Nov; 8(11):1525-32. PubMed ID: 7848589
[TBL] [Abstract][Full Text] [Related]
39. Expression of neutralizing recombinant human antibodies against Varicella Zoster virus for use as a potential prophylactic.
Lloyd-Evans P; Gilmour JE
Hybridoma; 2000 Apr; 19(2):143-9. PubMed ID: 10868794
[TBL] [Abstract][Full Text] [Related]
40. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates.
Allaway GP; Davis-Bruno KL; Beaudry GA; Garcia EB; Wong EL; Ryder AM; Hasel KW; Gauduin MC; Koup RA; McDougal JS
AIDS Res Hum Retroviruses; 1995 May; 11(5):533-9. PubMed ID: 7576908
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
